Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 14, 2019 - Merz Pharmaceuticals announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment of blepharospasm in adult patients.
Download PDF
Return to publications
